All stock lists
argenx SE (NASDAQ:ARGX)
NL · Delayed Price · Currency is USD
Healthcare · Biotechnology
$964.41-$16.91 (-1.72%)
Market cap
$59.9B
Insider Score
Health Score
Analyst consensus
Listed since
May 18, 2017
Website
Insider Score
––Not scored
ARGX Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Strong
From ARGX’s reported statements · Q3 2026 (trailing 12 months)
Profitability20 / 20
Keeps a healthy share of every dollar it sells.
- Revenue
- $8.69B
- Net income
- $2.64B
- Net margin
- 30.3%
Leverage20 / 20
Little or no net debt.
- Total debt
- $47.0M
- Cash
- $3.58B
- Net debt / EBITDA
- -1.30x
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $8.07B
- Current liabilities
- $1.57B
- Current ratio
- 5.12
Cash generation20 / 20
The business funds itself from operations.
- Operating cash flow
- $1.64B
- Free cash flow
- $1.63B
- FCF margin
- 18.7%
Dilution & runway16 / 20
Not funding itself by issuing shares.
- Shares outstanding
- 62.7M
- Share growth (1y)
- 4.4%
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
ARGX Income Statement
| Fiscal Period | Q3 2026 | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Period Ending | Sep 30, 2026 | Jun 30, 2026 | Dec 31, 2025 | Jun 30, 2025 | Dec 31, 2024 | Jun 30, 2024 |
| Revenue | $1.72 B | $2.82 B | $3.21 B | $947.96 M | $573.24 M | $401.00 M |
| Revenue Growth (YoY) | 200.23 % | 602.18 % | 871.99 % | 85.54 % | 83.33 % | 260.11 % |
| Cost of Revenue | $165.00 M | $279.27 M | $339.92 M | $110.75 M | $59.07 M | $43.18 M |
| Gross Profit | $1.56 B | $2.54 B | $2.87 B | $837.21 M | $514.16 M | $357.82 M |
| SG&A Expense | $598.00 M | $772.76 M | $355.00 M | $321.35 M | $277.70 M | $236.00 M |
| R&D Expense | $503.00 M | $486.00 M | $443.00 M | $327.70 M | $235.94 M | $224.97 M |
| Operating Expenses | $1.07 B | $1.69 B | $2.01 B | $633.37 M | $499.98 M | $451.24 M |
| Operating Income | $485.00 M | $846.83 M | $850.77 M | $203.84 M | $14.19 M | -$93.42 M |
| Pretax Income | $538.00 M | $958.94 M | $991.71 M | $286.90 M | $88.02 M | -$74.35 M |
| Tax Provision | $32.00 M | $119.12 M | -$54.97 M | $41.54 M | -$3.39 M | -$12.75 M |
| Net Income | $506.00 M | $838.82 M | $1.05 B | $245.36 M | $91.41 M | -$61.60 M |
| EPS (Basic) | $8.07 | $13.49 | $14.25 | $6.85 | $1.52 | -$1.04 |
| EPS (Diluted) | $7.80 | $13.02 | $13.22 | $6.37 | $1.39 | -$1.04 |
| Shares Outstanding | 62.74 M | 62.19 M | 61.42 M | 61.03 M | 60.09 M | 59.31 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.